DATA SHEET BARACLUDE QUALITATIVE AND …
Baraclude V5.0 1 DATA SHEET 1 BARACLUDE Baraclude® 0.5 mg film-coated Tablets Baraclude 1 mg film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Baraclude 0.5 mg tablets contain 0.5 mg of entecavir.
Download DATA SHEET BARACLUDE QUALITATIVE AND …
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
EXTERNAL REVIEW – THEOPHYLLINE - WHO archives
archives.who.intThis review therefore considers the evidence for the possible deletion of theophylline as a specific oral methylxanthine in relation to the listed
Psychotropic Medication Use in Dementia - Alz
www.alztex.org∗Epidemiology of psychiatric conditions in older adults ∗Psychotropic medications and their risks ∗Clinical decision making Outline
CANNABIDIOL (CBD) Pre-Review Report
www.who.intCANNABIDIOL (CBD) Pre-Review Report Agenda Item 5.2 Expert Committee on Drug Dependence Thirty-ninth Meeting Geneva, 6-10 November 2017
Update of Cannabis and its medical use - WHO
www.who.intUpdate of Cannabis and its medical use Bertha K. Madras Professor of Psychobiology Department of Psychiatry Harvard Medical School McLean Hospital
Aripiprazole Oral Once-Weekly - Drug Reformulation
www.zysis.comSummary The total market that an oral, once-weekly, patent-protected formulation of aripiprazole can target is 13.4 billion USD; Zysis forecast a 5.5% market share by …